Revvity, Inc. (RVTY) is a life sciences and diagnostics company that develops technologies, software, and services supporting ...

As instruments grow faster, leaders say clinical impact will depend on trust, standards, data, and assays built for real ...

Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI ...

U.S. Spatial Genomics and Transcriptomics Market to Grow from USD 0.26 Billion to USD 0.71 Billion by 2035, While Europe ...

AI drug discovery cleared its first Phase IIa clinical test in 2025, as BIO 2026 confirmed the shift from speculation to ...

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader ...

Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals One platform Governed data and ontology-driven ...

(Nasdaq: SEER) (“Seer” or the “Company”) today issued a letter to stockholders containing important information for shareholders to consider in connection with the Company’s upcoming Annual Meeting of ...

Samsung Electronics said Wednesday it has taken a strategic investor stake in genomics equipment company Element Biosciences, ...

Samsung Electronics Becomes Largest Shareholder in Element Biosciences Strategic Investment Accelerates Precision Medicine ...

MOFA is a factor analysis model that provides a general framework for the integration of multi-omic data sets in a completely unsupervised fashion. Intuitively, MOFA can be viewed as a versatile and ...

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London PO ...